Virax Biolabs (VRAX)

• Market cap: $2.64M
• 1 day: -1.06%
• 5 days: -5.5%
• 1 month: -0.23%
• 3 months: -33.85%
• 6 months: -38.74%
• Year to date: -72.46%
• 1 year: -60.99%
• 5 years: -99.67%
• 10 years: -99.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Employees: 19